Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview.
作者信息
Cultrera Rosario
机构信息
Infectious Diseases, Azienda Ospedaliero-Universitaria e Azienda Unità Sanitaria Locale di Ferrara, Ferrara - Italy.
Antimicrobial Stewardship Program Team, Azienda Ospedaliero-Universitaria e Azienda Unità Sanitaria Locale di Ferrara, Ferrara - Italy.
出版信息
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):1-4. doi: 10.33393/grhta.2024.3108. eCollection 2024 Jan-Dec.
Abstract
摘要
相似文献
1
Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview.
Glob Reg Health Technol Assess. 2024 Jul 29;11(Suppl 2):1-4. doi: 10.33393/grhta.2024.3108. eCollection 2024 Jan-Dec.
2
Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Pak J Pharm Sci. 2008 Jan;21(1):78-87.
3
Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Int J Antimicrob Agents. 2022 Feb;59(2):106503. doi: 10.1016/j.ijantimicag.2021.106503. Epub 2021 Dec 18.
4
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1125-1134. doi: 10.1080/14787210.2021.1894130. Epub 2021 Mar 16.
5
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Pharmacotherapy. 2010 Jan;30(1):80-94. doi: 10.1592/phco.30.1.80.
6
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
J Chemother. 2005 Dec;17(6):593-600. doi: 10.1179/joc.2005.17.6.593.
7
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Drug Des Devel Ther. 2021 Aug 3;15:3349-3378. doi: 10.2147/DDDT.S313756. eCollection 2021.
8
Dalbavancin: a new option for the treatment of gram-positive infections.
Ann Pharmacother. 2006 Mar;40(3):449-60. doi: 10.1345/aph.1G158. Epub 2006 Feb 28.
9
Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality.
Antibiotics (Basel). 2021 Oct 24;10(11):1296. doi: 10.3390/antibiotics10111296.
10
Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Int J Antimicrob Agents. 2018 Apr;51(4):571-577. doi: 10.1016/j.ijantimicag.2017.11.008. Epub 2017 Nov 24.
本文引用的文献
1
Antimicrobial Resistance (AMR).
Br J Biomed Sci. 2023 Jun 28;80:11387. doi: 10.3389/bjbs.2023.11387. eCollection 2023.
2
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin.
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(7):703-721. doi: 10.1080/14787210.2023.2214727. Epub 2023 May 31.
3
[Not Available].
Glob Reg Health Technol Assess. 2020 Nov 6;7:92-100. doi: 10.33393/grhta.2020.2138. eCollection 2020 Jan-Dec.
4
A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
J Glob Antimicrob Resist. 2022 Sep;30:390-394. doi: 10.1016/j.jgar.2022.07.018. Epub 2022 Jul 22.
5
A prospective multicentre screening study on multidrug-resistant organisms in intensive care units in the Dutch-German cross-border region, 2017 to 2018: the importance of healthcare structures.
Euro Surveill. 2022 Feb;27(5). doi: 10.2807/1560-7917.ES.2022.27.5.2001660.
6
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
7
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
Clin Pharmacokinet. 2022 Mar;61(3):363-374. doi: 10.1007/s40262-021-01088-w. Epub 2021 Dec 21.
8
Individual moral responsibility for antibiotic resistance.
Bioethics. 2022 Jan;36(1):3-9. doi: 10.1111/bioe.12958. Epub 2021 Oct 2.
9
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Clin Drug Investig. 2021 May;41(5):437-448. doi: 10.1007/s40261-021-01028-3. Epub 2021 Apr 21.
10
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02260-20. Epub 2021 Mar 1.
Zotero 插件